Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.

• Van Den Bent, Martin J. Erasmus MC Cancer Center, Rotterdam, Netherlands;
• Erridge, Sara South East Scotland Cancer Centre, Edinburgh, United Kingdom;
• Vogelbaum, Michael A. Cleveland Clinic Brain Tumor I, Cleveland, OH;
• Nowak, Anna K. Sir Charles Gairdner Hospital, Perth, WA, Australia;
• Sanson, Marc Universite Pierre Et Marie Curie-Paris 6, Centre de Recherche de L'institut Du Cerveau et de la Moelle Épinière (CRICM), Neurologie 2, Paris, France;
• Brandes, Alba Ariela Azienda USL Bellaria-Maggiore Hospital, Bologna, Italy;
• Wick, Wolfgang Neurology Clinic, Heidelberg, Germany;
• Clement, Paul M. UZ Leuven-Gasthuisberg, Leuven, Belgium;
• Baurain, Jean-Francois Oncologie Médicale Cliniques Universitaires Saint-Luc, Brussels, Belgium;
• Mason, Warren P. Princess Margaret Hospital, Toronto, ON, Canada;
• Wheeler, Helen Royal North Shore Hospital, Department of Oncology, St Leonards, Australia;
• Chinot, Olivier L. Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France;
• Weller, Michael University Hospital Zurich, Zurich, Switzerland;
• Golfinopoulos, Vassilis EORTC, Brussels, Belgium;
• Aldape, Ken Toronto General Hospital/Research Institute (UHN), Toronto, ON, Canada;
• Dinjens, Winand N.M. Erasmus University Medical Center, Rotterdam, Netherlands;
• Wesseling, Pieter Department of Pathology, VU University Medical Center, Amsterdam, Netherlands;
• Gorlia, Thierry EORTC Data Centre, Brussels, Belgium;
• Kros, Johan M Department of Neuropathology, Erasmus MC – Cancer Center, Rotterdam, Netherlands;
• Baumert, Brigitta G. University of Bonn Medical Centre, Bonn, Germany;

Cancer Research

Oncology